An observational study in Mixed Neuroendocrine-Non Neuroendocrine Neoplasm and Neuroendocrine Neoplasm, sponsored by European Institute of Oncology. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-21.
Sponsored by European Institute of Oncology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Neuroendocrine Tumors with a site in Italy — 20 open to participants now, 24 under way, 5 of them phase 3. Neuroendocrine Tumors · Italy.
Among the 68 studies in Neuroendocrine Tumors with a site in Italy, this one is the 11th largest by planned enrollment of the 18 observational ones that give a count, is one of 2 that started in 2024, is one of 18 observational ones, reaches primary completion later than 11 of the 23 other live ones, and was the 65th registered.
544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.
Browse Neuroendocrine Tumors studies →20 of the 68 studies in Neuroendocrine Tumors with a site in Italy are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Italy, United States, Brazil and 6 more countries
Ages 18+
Exelixis · Sites in Italy, United States, Australia and 15 more countries
Ages 18+
IRCCS San Raffaele · Sites in Italy
Ages 18+
Grupo Espanol de Tumores Neuroendocrinos · Sites in Italy, Belgium, France and 1 more country
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 29 · Phase 3 11 · Phase 4 5
First in 2002; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is close to the median of 134 across 130 observational studies indexed under Neuroendocrine Tumors.
Median enrollment 100 across the 50 interventional studies, 252 across the 18 observational. Of the 38 that completed or were terminated, 18 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 68 have an industry lead sponsor. The 10 most frequent:
European Institute of Oncology is the lead sponsor of 186 studies on the registry; 118 are open to participants now.
European Institute of Oncology has 8 studies filed under Neuroendocrine Tumors — fewer than ten, so there is no comparison to draw.
6 of the studies in Neuroendocrine Tumors with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04919226Phase 3ITM Solucin GmbHLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE | 2027-06 |
| NCT07087054Phase 3Crinetics Pharmaceuticals Inc.Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | 2027-08 |
| NCT06356467IRCCS San RaffaeleInfluence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs | 2026-12-31 |
| NCT06337760European Institute of OncologyYOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs. | 2026-12-31 |
| NCT07903532Instituto de Investigación Sanitaria de la Fundación Jiménez DíazMulticenter Study for External Validation of the TB-NET Score | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 68 studies in Neuroendocrine Tumors with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
For GEP mixed neuroendocrine (NE) non-neuroendocrine neoplasms (MiNENs) a key issue affecting prognosis is sometimes the difficulty in obtaining a timely diagnosis, as the NE component is often localized in deeper anatomical locations and/or becomes prevalent over time. The tissue material of biopsies may be not enough to define the NE component when this is particularly small and this could impact on therapeutic decision. Furthermore GEP NENs need to be characterized for potentially druggable biomarkers and liquid biopsy has clear advantage to the solid one to this aim. Here, we will exploit epigenetic differences characterizing NE tumors to build a DNA methylation-based liquid biopsy assay able to detect circulating tumor DNA of NE derivation, to enable the non-invasive diagnosis and monitoring of GEP-MiNENs.
GEP-NENs are a heterogeneous group of diseases that encompasses relatively indolent and more aggressive tumors, sometimes with mixed exocrine/endocrine components (MINENs). Due to persistent uncertainties in diagnosis and treatment, prognosis of the mixed and more aggressive forms remains poor. Non-invasive tests would enable timely identification and monitoring over time. A better understanding of their biology and of the phenotypic differentiation process may pave the way for novel therapies. Differentiation follows, and can be inferred from, changes in the epigenetic landscape that shape transcriptional programs. Among epigenetic markers, DNA methylation is particularly well suited for non-invasive detection as it can be measured in circulating tumor DNA (ctDNA). New technologies like Oxford Nanopore Technologies (ONT) enable simultaneous analysis of DNA sequence and methylation, as we recently showed by Magi et al Nat Comms Biol 2022. Previous studies identified distinct neuroendocrine epi-transcriptomic landscapes but were conducted on tumor specimens (Yachida et al Cancer Discov 2022), impeding the discrimination of signals specifically generated within neuroendocrine tumor cells from the noise due to surrounding nontumoral or exocrine tumoral cells. This is now potentially solved by methods allowing single-cell sequencing directly from frozen or paraffin-embedded patient samples.
The main expected outcome is the development of a novel liquid biopsy assay for the detection and monitoring of GEP-NENs and MiNENs. To this end, we will exploit the ability of Oxford Nanopore Technologies (ONT) sequencing to simultaneously yield sequencing and methylated DNA profiles. Importantly, assessment of cell of origin from ctDNA requires the comparison of methylation and fragmentomics signals with previously generated maps of reference cells and tissues (Katsman et al 2022 Genome Biology). For rare tumors like NENs, these maps are not available in the literature; the few studies that have characterized the epigenomic features of NENs are likely contaminated by the surrounding stroma, so epigenetic signals (including both DNA methylation and tumor-specific transcription factor binding sites, essential for fragmentomics) may be uninformative for detection in the blood.
Patients with GEP-NENs, aiming to collect adequate material and for a formal clinical to establish sensitivity and specificity of the assay in a clinically meaningful scenario.
Due to the relative rarity of the disease compared to non-NENs we will not enroll a consecutive population, but we will set up a case-control study:
Patients will be enrolled as cases or controls based on their pre-surgical diagnostic biopsy but will be definitively allocated in the case or control group based on their post-surgery full histological examination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient histologically confirmed non-NEN histotype:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patient with histologically confirmed neuroendocrine neoplasm and onfirmed Mixed Neuroendocrine-non neuroendocrine neoplasm with each component \> 30%) and high-grade Neuroendocrine Carcinomas
patient with histologically confirmed non-neuroendocrine gastrointestinal tumors (including gastric, pancreatic, colorectal, small intestine).
Develop a circulating methDNA/fragmentomics diagnostic assay
Epigenetic differences characterizing neuroendocrine tumors will be exploited to build a DNA methylation-based liquid biopsy assay able to detect circulating tumor DNA of neuroendocrine derivation, to enable the non-invasive diagnosis and monitoring of GEP-MiNENs.
Time frame: 2 years
Started Oct 2024 (actual). Primary completion is estimated for Oct 2026, 24 months after the start.
Of 54 observational studies under Neuroendocrine Tumors, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 239. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
European Institute of Oncology →